As of 2025-09-17, the EV/EBITDA ratio of Foghorn Therapeutics Inc. (FHTX) is -2.44. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FHTX's latest enterprise value is 204.43 mil USD. FHTX's TTM EBITDA according to its financial statements is -83.81 mil USD. Dividing these 2 quantities gives us the above FHTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.4x - 14.3x | 13.4x |
| Forward P/E multiples | 16.3x - 33.6x | 19.1x |
| Fair Price | (22.88) - (19.89) | (22.81) |
| Upside | -567.0% - -505.9% | -565.5% |
| Date | EV/EBITDA |
| 2025-09-16 | -2.44 |
| 2025-09-15 | -2.50 |
| 2025-09-12 | -2.63 |
| 2025-09-11 | -2.70 |
| 2025-09-10 | -2.61 |
| 2025-09-09 | -2.80 |
| 2025-09-08 | -3.01 |
| 2025-09-05 | -3.03 |
| 2025-09-04 | -2.77 |
| 2025-09-03 | -2.69 |
| 2025-09-02 | -2.70 |
| 2025-08-29 | -2.55 |
| 2025-08-28 | -2.51 |
| 2025-08-27 | -2.78 |
| 2025-08-26 | -2.86 |
| 2025-08-25 | -2.68 |
| 2025-08-22 | -2.88 |
| 2025-08-21 | -2.53 |
| 2025-08-20 | -2.68 |
| 2025-08-19 | -2.39 |
| 2025-08-18 | -2.57 |
| 2025-08-15 | -2.49 |
| 2025-08-14 | -2.60 |
| 2025-08-13 | -2.62 |
| 2025-08-12 | -2.42 |
| 2025-08-11 | -2.31 |
| 2025-08-08 | -2.22 |
| 2025-08-07 | -2.49 |
| 2025-08-06 | -2.44 |
| 2025-08-05 | -2.51 |
| 2025-08-04 | -2.60 |
| 2025-08-01 | -2.50 |
| 2025-07-31 | -2.68 |
| 2025-07-30 | -2.81 |
| 2025-07-29 | -3.12 |
| 2025-07-28 | -3.52 |
| 2025-07-25 | -3.31 |
| 2025-07-24 | -3.31 |
| 2025-07-23 | -3.50 |
| 2025-07-22 | -3.41 |
| 2025-07-21 | -3.25 |
| 2025-07-18 | -3.27 |
| 2025-07-17 | -3.25 |
| 2025-07-16 | -3.10 |
| 2025-07-15 | -3.05 |
| 2025-07-14 | -3.10 |
| 2025-07-11 | -2.78 |
| 2025-07-10 | -2.78 |
| 2025-07-09 | -2.85 |
| 2025-07-08 | -2.43 |